Partnership between Oklo and Atomic Alchemy for isotope production

Oklo Inc. and Atomic Alchemy launch a partnership to increase the production of industrial and medical isotopes, essential in various sectors including cancer treatment.

Share:

Partenariat Oklo Atomic Alchemy Isotope

Comprehensive energy news coverage, updated nonstop

Annual subscription

8.25$/month*

*billed annually at 99$/year for the first year then 149,00$/year ​

Unlimited access • Archives included • Professional invoice

OTHER ACCESS OPTIONS

Monthly subscription

Unlimited access • Archives included

5.2$/month*
then 14.90$ per month thereafter

FREE ACCOUNT

3 articles offered per month

FREE

*Prices are excluding VAT, which may vary depending on your location or professional status

Since 2021: 35,000 articles • 150+ analyses per week

Against a backdrop of worldwide shortages of medical and industrial isotopes, Oklo Inc. and Atomic Alchemy announce strategic partnership to increase production of essential isotopes. This partnership leverages Oklo’s capabilities in fast fission technology and nuclear fuel recycling with Atomic Alchemy’s expertise in isotope production. Together, they plan to build and operate fast reactors that will not only be a source ofclean energy production, but also a platform for the production of vital isotopes for medical diagnostics, cancer treatment and industrial applications.

Technology and innovation at the heart of the partnership

Oklo’s fast reactors and advanced fuel recycling processes form the technological basis of this partnership. These technologies will enable the production of a wide range of isotopes, including those currently in critical short supply, such as those used in radioisotope thermoelectric generators and advanced cancer therapies. Oklo uses a reactor technology that optimizes the use of nuclear fuel and minimizes waste, while increasing the efficiency of isotope production.

Economic and security implications

This partnership is strategic not only from a technological point of view, but also from an economic and security one. By increasing domestic isotope production, the USA could reduce its dependence on foreign sources, often located in geopolitically unstable areas. This initiative is all the more relevant given that global demand for medical isotopes is rising steadily, fuelled by advances in cancer diagnosis and treatment technologies.

Challenges and prospects

The partnership between Oklo and Atomic Alchemy is not without its challenges. The complexity of isotope production requires considerable investment in research and development, as well as strict regulatory safeguards to ensure the safety and efficacy of the isotopes produced. However, the heads of both companies, Jacob DeWitte of Oklo and Thomas Eiden of Atomic Alchemy, are confident in their ability to overcome these obstacles thanks to their combined expertise and the support of their strategic and financial partners.
The partnership between Oklo and Atomic Alchemy is a bold step forward in securing the supply of isotopes vital to many sectors. It represents not only a technological breakthrough, but also a strategic initiative that could redefine energy production and public health standards in the United States.

French nuclear reactor developer Newcleo has submitted its lead-cooled small modular reactor design to Euratom, initiating the first regulatory phase to integrate nuclear non-proliferation safeguards at the European level.
French state utility EDF has increased the maximum estimated cost for building six new nuclear reactors to €72.8 billion ($85.29 billion), representing a 40% rise over the original figure.
US-based Holtec has signed a memorandum of understanding with Hungary’s energy group MVM to assess the deployment of its SMR-300 technology, strengthening bilateral nuclear cooperation and opening prospects for a new market in Central Europe.
California-based startup Radiant has secured $300mn to build its first factory in Tennessee and prepare for the mass production of miniature nuclear reactors for off-grid applications.
Terra Innovatum has increased its interactions with the Nuclear Regulatory Commission to advance licensing of its SOLO™ micro-modular reactor, despite the partial shutdown of the US federal government.
The US nuclear regulator has extended the operating licences of three Illinois reactors by 20 years, strengthening Constellation's long-term industrial outlook for the Clinton and Dresden sites.
The SATURNE Industrial Chair aims to develop innovative uranium extraction methods, with joint funding from Orano and the National Research Agency over a four-year period.
US-based X-energy has signed a reservation agreement with South Korea's Doosan Enerbility to secure key components for its small modular nuclear reactors.
Niger expands its mining alliances with Uranium One to develop new sites, while the Dasa project continues seeking financing despite clear political backing.
Samsung Heavy Industries has received Approval in Principle for a floating nuclear plant featuring two SMART100 reactors, marking a step toward the commercialisation of offshore small modular reactors.
The Indian government proposes a unified legal framework for nuclear energy, aiming to boost private investment and increase installed capacity to 100 GW by 2047.
Samsung C&T strengthens its presence in modular nuclear energy in Europe by signing an agreement with Synthos Green Energy to develop up to 24 SMRs in Poland and several Central European countries.
Israeli firm nT-Tao and Ben-Gurion University have developed a nonlinear control system that improves energy stability in fusion plasmas, strengthening the technical foundation of their future compact reactors.
The Indian government has introduced a bill allowing private companies to build and operate nuclear power plants, ending a state monopoly in place for over five decades.
Natura Resources enters a new regulatory phase for its molten salt reactor MSR-1, following the signing of a framework agreement with the US Department of Energy under the Reactor Pilot Program.
Norwegian Nuclear Decommissioning is surveying 22 localities to assess their interest in hosting storage facilities for radioactive waste from the country’s former research reactors.
Electricité de France's Flamanville 3 reactor has reached full power for the first time, marking a key industrial milestone in the deployment of EPRs in Europe, despite cost overruns reaching EUR23.7bn ($25.7bn).
GE Vernova Hitachi’s BWRX-300 small modular reactor has passed a key regulatory hurdle in the United Kingdom, opening the door to potential commercial deployment, despite no current plans for construction.
Molten salt reactor developer Natura Resources has acquired Shepherd Power and partnered with NOV to scale up modular reactor manufacturing by the next decade.
China National Nuclear Corporation expects commercial operation in 2026 for its ACP100 reactor, following successful cold testing and completion of critical structures in 2025.

All the latest energy news, all the time

Annual subscription

8.25$/month*

*billed annually at 99$/year for the first year then 149,00$/year ​

Unlimited access - Archives included - Pro invoice

Monthly subscription

Unlimited access • Archives included

5.2$/month*
then 14.90$ per month thereafter

*Prices shown are exclusive of VAT, which may vary according to your location or professional status.

Since 2021: 30,000 articles - +150 analyses/week.